Clarivate™

Market insights summary

U.S. ventricular assist device market

What's trending?

Positive clinical study results will drive temporary percutaneous VAD[1] use

- Positive results from the DanGer Shock trial resulted in an upgraded recommendation for Abiomed's (part of Johnson & Johnson MedTech) Impella temporary VADs, which will drive greater uptake.
- Encouraging initial results from the Impella ECP pivotal trial are expected to lead to U.S. FDA[2] approval for this temporary VAD in late 2025.

Safety concerns are leading to declining durable VAD use

- In 2024, the U.S. FDA issued a series of Class I recalls for Abbott Laboratories' HeartMate series of devices. The more invasive nature of durable VAD procedures, along with these recent safety concerns, will lead to declining durable VAD procedure volumes.
- Nonetheless, the increasing average prices of durable VADs, along with the expected introduction of fully-implantable durable VADs by Abbott Laboratories during the forecast period, will mitigate revenue declines.

Access more insights and data in the report.
Speak to our team to see how we can power your innovation.

[1]VAD = Ventricular assist device
[2]FDA = Food and Drug Administration
*Limited to temporary VADs

2023 U.S. market snapshot

$1.42B
Market value

9.9%
CAGR (2023 – 2033)

U.S. VAD[1] procedure growth by product type (2023 - 2033)



U.S. VAD market value (2023 vs. 2033)



U.S. VAD market revenue share



U.S. VAD procedures by durability and technique